Medicines planning
51 results
Applied filters
Costing Clinical Trials of ATIMPs using the NIHR iCT - Advice for Pharmacy Sites
12 July 2022Guidance to support and promote consistent pharmacy costing for commercial clinical trials involving ATIMPs.
The licence and supporting evidence for eculizumab biosimilars
6 March 2024Two licensed eculizumab biosimilars are available: Bekemv and Epysqli. Learn about the licensed indications, supporting evidence and key differences.
Good governance when implementing natalizumab biosimilar
6 February 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.
National Homecare Medicines Committee (NHMC) Managing Complaints and Incidents within Homecare Services - Appendix 19 training
2 July 2018In November 2016, the Royal Pharmaceutical Society (RPS) published Appendix 19 of the Royal Pharmaceutical Society (RPS) Handbook for Homecare Services in England i.e. ‘Further…
National Homecare Medicines Committee (NHMC) Proposal for the funding of Pharmacy Homecare Teams
4 May 2018NHMC submitted a proposal for the funding of Trust Pharmacy Homecare Teams to NHS England and NHS Clinical Commissioning for consideration. The NHMC hopes that…
National Homecare Medicines Committee (NHMC) Homecare Risk Assessment
10 December 2019To support organisations in establishing a robust risk assessment process for new homecare medicines services the NHMC has developed a tool for local use. …
NHMC Good Practice Principles for the Provision of Manufacturer Funded Homecare Services
5 March 2018These Good Practice Principles set out the National Homecare Medicines Committee’s (NHMC) expectations of Manufacturers offering Manufacturer Funded Homecare Medicine Services in relation to the…
Good governance when implementing tocilizumab biosimilar
5 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
Planning
We support organisations with the planned introduction of medicines. We create annual review products as well as ongoing updates to keep you informed.
Preparing to use golimumab biosimilar
21 May 2025Golimumab biosimilars are expected soon. We offer general information and implementation advice.